Is chimeric antigen receptor T cell (CART) a destination procedure? Lower socioeconomic class who live farther from center have less access to CART
| Autor: | Muhammad Umair Mushtaq, Marc Hoffmann, Rajat Bansal, Sunil Abhyankar, Allison Appenfeller, Leyla Shune, Crissy Kus, Aung M. Tun, Nausheen Ahmed, Siddhartha Ganguly, Ernie Shippey, Joseph P. McGuirk, Clint Devine |
|---|---|
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | Journal of Clinical Oncology. 39:e18562-e18562 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2021.39.15_suppl.e18562 |
| Popis: | e18562 Background: Axicabtagene ciloleucel and tisagenlecleucel are commercially available CD19 chimeric antigen receptor T-cell (CART) therapies for B cell malignancies. Manufacturing pharmaceutical companies require patients to stay within 2 hours of the center for 4 weeks post infusion. Most centers require local lodging for that period if residence is over 30 minutes away. Financial burden may limit access. We therefore hypothesized that those who were likely to receive CART therapies were from higher income neighborhoods or lived closer to the facility. Methods: Since most patients get admitted for CART infusion, we used the Vizient CDB database for CART infusion admissions as well as other admissions. Patients over the age of 18 yrs who got commercially available CART between 2018 to 2020 were included. Distance was calculated in miles from patient zip code to treating center. Using census data, lower income neighborhoods (less than $40,000 median household income) were flagged. Results: 81 centers administered CART. We calculated the distance in miles between the patient and the center for both CART admissions as well as for all-cause inpatient admissions. Most admissions (81.2% all-cause vs 78.6% CART) were from neighborhoods with median income > $40,000. Most of the low-income admissions were from neighborhoods 60 miles. (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|